DPP4 and congenital bilateral aplasia of vas deferens from CFTR mutation: As mechanistic studies identify new mediators of CAVD, existing drugs such as DPP4 inhibitors currently used in the treatment of diabetes may become candidates for the treatment of CAVD (208).